Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
Crossref DOI link: https://doi.org/10.1007/s10549-015-3615-9
Published Online: 2015-10-24
Published Print: 2015-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Blackwell, Kimberly
Burris, Howard
Gomez, Patricia
Lynn Henry, N.
Isakoff, Steven
Campana, Frank
Gao, Lei
Jiang, Jason
Macé, Sandrine
Tolaney, Sara M.
Funding for this research was provided by:
Sanofi
Text and Data Mining valid from 2015-10-24